Basel, Switzerland – Novartis, a global leader in innovative medicines, today announced it has reached an agreement with the U.S. government to help lower the price of medicines in the United States while continuing to invest in domestic research, development, and manufacturing.
Under this agreement, Novartis will take several actions to support U.S. drug pricing priorities, including:
- Launching new medicines at prices comparable to those in other high-income countries.
- Expanding direct-to-patient access for medicines such as Mayzent® (siponimod), Rydapt® (midostaurin), and Tabrecta® (capmatinib) through the TrumpRx platform.
- Participating in the GENERIOUS (GENErating cost Reductions fOr U.S. Medicaid) Model to further improve access for Medicaid patients.
- Supporting broader efforts to balance global investment in pharmaceutical innovation.
“This agreement reflects our ongoing commitment to working with the U.S. government to ensure patients have access to innovative treatments,” said Vas Narasimhan, CEO of Novartis. “We remain dedicated to advancing research and manufacturing capabilities in the United States while ensuring our medicines are accessible to those who need them.”
Earlier this year, Novartis committed $23 billion over five years to expand U.S. research and manufacturing infrastructure. Key initiatives include:
- Establishing a $1.1 billion biomedical research hub in San Diego, CA.
- Building a new flagship manufacturing hub in North Carolina, with three new facilities in the Raleigh/Durham area.
- Opening a radioligand therapy manufacturing facility in Carlsbad, CA, and advancing plans for additional facilities in Florida and Texas.
- In recognition of these investments, Novartis expects to receive three years of tariff relief.
About Novartis
Novartis is a global healthcare company dedicated to discovering, developing, and delivering innovative medicines that improve and extend people’s lives. The company’s medicines reach nearly 300 million people worldwide.
By